Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Percheron Therapeutics ( (AU:PER) ) has shared an announcement.
Percheron Therapeutics has launched a non-renounceable pro-rata entitlement offer, giving eligible shareholders the right to subscribe for two new shares for every five held at an issue price of $0.005 per share, with one free attaching option for every two new shares subscribed, exercisable at $0.01 within two years. The company has also established a shortfall offer on the same terms for any securities not taken up, but has formally notified shareholders outside Australia, New Zealand, Singapore, Hong Kong and the United Kingdom that they are ineligible to participate due to cost and regulatory considerations, meaning these investors will not receive the prospectus or be able to subscribe for new shares or options.
The most recent analyst rating on (AU:PER) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Percheron Therapeutics stock, see the AU:PER Stock Forecast page.
More about Percheron Therapeutics
Percheron Therapeutics Limited is an Australia-based biotechnology company listed on the ASX under the ticker PER. The company is focused on developing therapeutic products, and its shareholder base is primarily concentrated in Australia and select international markets, including New Zealand, Singapore, Hong Kong and the United Kingdom.
Technical Sentiment Signal: Sell
Current Market Cap: A$7.61M
For a thorough assessment of PER stock, go to TipRanks’ Stock Analysis page.